Spruce Biosciences (SPRB) vs. The Competition Financial Survey

Spruce Biosciences (NASDAQ:SPRB) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Spruce Biosciences to similar businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Institutional and Insider Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Spruce Biosciences and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Spruce Biosciences Competitors	-12,359.35%	-203.09%	-30.93%

Volatility and Risk

Spruce Biosciences has a beta of 3.57, meaning that its stock price is 257% more volatile than the S&P 500. Comparatively, Spruce Biosciences’ competitors have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Spruce Biosciences and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	0	11	0	2.83
Spruce Biosciences Competitors	9846	15129	45498	1589	2.54

Spruce Biosciences currently has a consensus target price of $158.33, suggesting a potential upside of 220.90%. As a group, “Biotechnology” companies have a potential upside of 97.90%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than its competitors.

Valuation and Earnings

This table compares Spruce Biosciences and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spruce Biosciences	$4.91 million	-$38.97 million	-1.24
Spruce Biosciences Competitors	$698.09 million	$10.43 million	-15.42

Spruce Biosciences’ competitors have higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Spruce Biosciences beats its competitors on 8 of the 13 factors compared.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.